Search Results for citation:"89 FR 107146"

Found 2 results
Skip to main content

Search Results: citation:"89 FR 107146"

  • Type:Notice
    Citation:89 FR 107146
    Reading Time:about a minute or two

    The Food and Drug Administration (FDA) is withdrawing approval for two abbreviated new drug applications (ANDAs) from Flamingo Pharmaceuticals Ltd. This decision is because the company has consistently failed to submit the necessary annual reports for these drug applications. Despite being given a chance for a hearing, the company did not respond, resulting in a waiver of their hearing opportunity and any claims about the drug's legal status. Therefore, the approval for these drugs will officially be withdrawn on December 31, 2024.

    Simple Explanation

    The FDA, which makes sure medicines are safe, decided to stop letting Flamingo Pharmaceuticals sell two of their medicines because the company didn't send in their homework about the medicines on time.

  • Type:Notice
    Citation:89 FR 107146
    Reading Time:about 2 minutes

    The Office of Child Support Services (OCSS) is seeking input from the public for changes to the State Plan for Child Support Collection and Establishment of Paternity under Title IV-D of the Social Security Act. These revisions are in line with a new rule that allows states to provide employment and training services to non-custodial parents involved in the child support program. This means that states opting into these services need to update their State Plans accordingly. The public can send comments within 30 days of this notice using specific platforms or by email.

    Simple Explanation

    The Office of Child Support Services wants to change some of their plans so they can help parents who don’t live with their kids get jobs and training, and they're asking people what they think about these changes. They're also figuring out how these changes might cost and how they can make sure everything works well.